Home
   Links
   Faculty Information
   Activities & Events
   Melanoma Care Centers
 
   Slide Library
   Polling Results
   Patient Resources
 
   Contact Us
   Register
   Log-in
   
 
 
 
 
 
 
 
 
 
Log In

Expired

Although this activity is no longer certified for credit, we believe that it contains important information and hope you'll review, print or email it to a colleague.

Activity:

Melanoma: Update on Emerging Therapies 1

Featured Topic Information:
Please click here to view a webcast (registration required)
Please click here to view this on your iDevice (registration required)
Please click here if you have any comments or questions relating to this topic

Continuing Medical Education Information

Date of Original Release: May 8, 2012
Expiration Date:
May 8, 2013
Date of last review:
April 4, 2012

Presenter:

Ahmad A. Tarhini, MD, PhD
Assistant Professor of Medicine
Clinical and Translational Science Institute
University of Pittsburgh
Pittsburgh, PA

Instructions For Participation

  • View the video presentation.
  • Complete the posttest and evaluation form that follows the presentation, and then click "submit."
  • You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the activity.

To receive a maximum of 0.50 AMA PRA Category 1 Credits™ for this activity:

  • Within 4 weeks of successful completion, you may access your credit transcript at http://ccehs.upmc.edu/
    • CME Course # 3755
  • 70% of your posttest answers must be correct for you to receive a certificate of credit

To receive up to 0.50 CNE credits for this activity:

  • Within 4 weeks of successful completion, a certificate will be mailed to the address provided
  • Within 4 weeks of successful completion, you may access your credit transcript at http://ccehs.upmc.edu/
    • CNE Course # 3779
  • 70% of your posttest answers must be correct for you to receive a certificate of credit

Target Audience

This activity is directed toward surgical oncologists, general surgeons, oncology nurses, medical oncologists, dermatologists, and other healthcare professionals who treat or screen for melanoma.

Statement Of Need

Melanoma kills 1 person every hour in the United States. It is a devastating disease with a rising incidence. Melanoma is the most common cancer in women age 25 to 29, is the number one cancer killer of women age 30 to 35, and takes the greatest toll of all cancers on women and men in terms of average years of life lost, because it afflicts young patients to such a great extent.

Management of melanoma remains challenging for all members of the health care team. Assessing risk, getting patients into the healthcare system, evaluating prognostic information, choosing appropriate therapy, working as a team, and educating, guiding and motivating the patient remain challenging. While many healthcare providers are exposed to patients with the potential for melanoma, a core group of specialists are most knowledgeable about the optimal management of this malignancy. These specialists will be the ones to interpret the new information gathered from ongoing research and studies, and to provide suggestions on how to incorporate new treatments into existing disease management algorithms.

Learning Objectives

Upon proper completion of this activity, participants should be better able to:

  • Evaluate the role of adjuvant interferon-α therapy in patients with melanoma
  • Discuss the potential prognostic markers for response to adjuvant interferon-α therapy in patients with melanoma
  • Identify patients who may benefit from BRAF inhibitor therapy.

For reading resources related to this activity, click here

Accreditation And Credit Designation

The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Pittsburgh School of Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Each physician should claim only the credit commensurate with the extent their participation in the activity.

0.50 contact hours of Continuing Nursing Education will be granted by The University of Pittsburgh Medical Center (UPMC). UPMC is an approved provider of continuing nursing education by the Pennsylvania State nurses Association (PSNA), an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Disclosure Of Commercial Support

We gratefully acknowledge an educational grant from Bristol-Myers Squibb and Merck in support of this activity.

Contributing Faculty & Disclosures

In accordance with Accreditation Council for Continuing Medical Education requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.

John M. Kirkwood, MD (Chair)
Director, Melanoma and Skin Cancer Program
University of Pittsburgh Cancer Institute
Professor of Medicine, Dermatology and Translational Science
University of Pittsburgh School of Medicine
Pittsburgh, PA

Research Support: Prometheus
Speaker's Bureau: Merck
Consultant: GlaxoSmithKline
SAB participant: Novartis

Ahmad A. Tarhini, MD, PhD
Assistant Professor of Medicine
Clinical and Translational Science Institute
University of Pittsburgh
Pittsburgh, PA
Consultant: Genentech, Prometheus

UPMC Center for Continuing Education in the Health Sciences/Paradigm Medical Communications, LLC staff members have no financial conflicts to disclose.

Independent peer reviewer has no financial conflicts to disclose.

Paradigm Medical Communications, LLC.
523 Route 303
Orangeburg, NY 10962

© Paradigm Medical Communications, 2012, except where noted. This webcast may not be reproduced in whole or part without the express written permission of Paradigm Medical Communication, LLC.

This CME program represents the views and opinions of the individual faculty for each case and does not constitute the opinion or endorsement of the editors, the advisory board, the publishing staff, Paradigm Medical Communications, the UPMC Center for Continuing Education in the Health Sciences, UPMC/University of Pittsburgh Medical Center or affiliates, or University of Pittsburgh School of Medicine.

Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions, including without limitation, FDA-approved uses, and any off-label uses.